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EFFECTS OF ABNORMAL LYSYL OXIDASE EXPRESSION  
IN DIABETIC RETINOPATHY 
 
DONGJOON KIM 
 
ABSTRACT 
 
Background: Retinal capillary basement membrane thickening is closely associated with 
the development of vascular lesions in diabetic retinopathy. Thickened capillary basement 
membrane can compromise blood-retinal-barrier (BRB) characteristics and contribute to 
retinal vascular permeability, a significant clinical manifestation of diabetic retinopathy. 
We have previously shown that high glucose (HG) increases the expression and activity of 
lysyl oxidase (LOX), a crosslinking enzyme, in retinal endothelial cells. Additionally, 
concomitant with overexpression of LOX, increased vascular permeability was observed 
in diabetic rat retinas. However, it is unknown whether decreasing LOX overexpression 
may have protective effects against development of retinal vascular lesions associated with 
diabetic retinopathy.  
 
Objective: To investigate whether reducing LOX level protects against diabetes-induced 
development of retinal vascular lesions characteristic of diabetic retinopathy  
 
  vi 
Methods:  In Experiment 1, wild type (WT) control mice, streptozotocin (STZ)-induced 
diabetic mice, LOX heterozygous knockout (LOX +/-) mice, and STZ-induced diabetic 
LOX +/- mice were used in the study. In Experiment 2, WT rats, diabetic rats, and diabetic 
rats intravitreally injected with LOX short interfering RNA (siRNA), or scrambled siRNA 
as control, were used in the study. 1 month after the onset of diabetes, intravitreal injections 
were initiated at monthly intervals for up to 3 times. At the end of the study, retinas were 
assessed for LOX protein level by Western Blot (WB) analysis, and retinal capillary 
networks were assessed for the number of acellular capillaries (AC) and pericyte loss (PL). 
Vascular leakage was analyzed by measuring the extravasation of FITC-dextran in retinal 
capillaries after tail vein injection of FITC-Dextran.  
 
Results: A significant increase in LOX expression was detected in the diabetic retinas 
compared to those of the WT control retinas while a significant decrease in LOX 
expression was observed in the diabetic LOX +/- retinas and in the diabetic retinas injected 
with LOX siRNA. Importantly, when diabetes-induced LOX overexpression was reduced, 
retinal vascular cell loss and vascular leakage were ameliorated.  
 
Conclusion: Decreasing diabetes-induced LOX overexpression may have protective 
effects against the development of vascular lesions characteristic of diabetic retinopathy. 
Therefore, LOX overexpression may be a potential target in preventing retinal vascular cell 
loss and excess permeability associated with diabetic retinopathy.  
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INTRODUCTION 
 
Diabetic retinopathy is a leading cause of blindness and vision loss in the middle-aged and 
elderly population worldwide (Sivaprasad, Gupta, Crosby-Nwaobi, & Evans, 2012; Ting, 
Cheung, & Wong, 2016). Unfortunately, there is no cure available for this ocular 
complication.  Diabetic retinopathy is the most common microvascular complication of 
diabetes and is becoming an increasing health burden worldwide, with estimates between 
1990 and 2010 showing that diabetic retinopathy-related visual impairment increased by 
64% and diabetic retinopathy-related blindness by 27%, globally (Duh, Sun, & Stitt, 2017). 
In addition to presenting public health challenges, diabetes also poses a hefty economic 
burden. In the United States, the total estimated cost of diabetes in 2012 was $245 billion, 
comprised of $176 billion in direct medical costs and $69 billion in reduced productivity 
(Ting et al., 2016). These findings point to a dire need to come up with treatments to address 
the growing global rates of diabetes and its complications, including diabetic retinopathy. 
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Figure 1. Global prevalence of diabetes and diabetic retinopathy. Figure taken from 
http://atlas.iapb.org/vision-trends/diabetic-retinopathy/ 
 
Pathophysiology of diabetic retinopathy 
Diabetic retinopathy can progress from a mild, non-proliferative stage to a moderate and 
severe non-proliferative diabetic retinopathy, to a proliferative stage where new retinal 
blood vessels grow uncontrollably and can lead to vision loss (Wong, Cheung, Larsen, 
Sharma, & Simo, 2016). Additionally, exudates may form and macular edema may occur, 
leading to sight-threatening diabetic macular edema (Wong et al., 2016). The pathogenesis 
of diabetic retinopathy has been attributed to duration of diabetes namely prolonged 
periods of hyperglycemia (Chatziralli, 2018). Interestingly, a study showed that with every 
1% decrease in HbA1c level, there was a reduction in 40% of diabetic retinopathy 
development, 25% need for laser-based therapy, 25% progression to vision threatening 
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diabetic retinopathy, and 15% blindness in diabetic patients (Ting et al., 2016), highlighting 
the importance of tight glycemic control to manage this ocular disease. Importantly, two 
landmark studies have clearly demonstrated that lowering blood glucose levels slows the 
onset and progression of diabetic retinopathy in both type 1 (Aiello & Group, 2014) and 
type 2 diabetic patients (American Diabetes, 2000).   
 
Diabetic retinopathy is characterized by early retinal vascular lesions such as the formation 
of AC and PL, death of vascular cells in the retinal capillary network (Roy, Ha, Trudeau, 
& Beglova, 2010). Retinal vascular basement membrane thickening, a histological 
hallmark of diabetic retinopathy, may promote apoptosis and thus lead to retinal vascular 
cell loss. While current treatments such as anti-VEGF therapy are effective (Osaadon, 
Fagan, Lifshitz, & Levy, 2014), they have a limited duration of efficacy and use of pan-
retinal photocoagulation pose side-effects, which makes the treatment not suitable for all 
diabetic retinopathy patients (Frank, 1980). Therefore, a growing demand exists for new 
therapies to treat vascular lesions associated with diabetic retinopathy. 
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Figure 2. Clinical manifestations of diabetic retinopathy. Figure taken from (Wong et 
al., 2016) 
 
The occurrence of retinal capillary basement membrane thickening in diabetes has been 
observed previously (Ashton, 1949; Kozak, Marker, & Elmer, 1986; Naccarato et al., 1970) 
and has been shown to be contributing to the pathogenesis of diabetic retinopathy (Roth, 
Podesta, Stepp, Boeri, & Lorenzi, 1993; Roy, Cagliero, & Lorenzi, 1996; Roy, Maiello, & 
Lorenzi, 1994). However, the implications of this ultrastructural alteration in the context 
of diabetic retinopathy are only beginning to be understood. Specifically, vascular 
basement membrane thickening has been shown to promote the development of AC, PL 
(Roy, Sato, Paryani, & Kao, 2003), and excess permeability (Oshitari et al., 2006) 
associated with diabetic retinopathy. While it may be paradoxical that thickened basement 
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membranes are associated with retinal vascular leakage, current understanding suggests 
that changes in the cross-linking of basement membrane components could influence the 
assembly and ultrastructure of the basement membrane and thereby compromise BRB 
characteristics (Chronopoulos, Tang, Beglova, Trackman, & Roy, 2010; Defronzo, 1997), 
leading to vascular leakage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of diabetes or hyperglycemia on vascular basement membrane 
thickening leading to diabetic retinopathy. New studies suggest that LOX may play a 
role in altering the ultrastructural integrity of the basement membrane, contributing to 
retinal vascular cell loss and vascular leakage associated with diabetic retinopathy. Figure 
taken from (Roy et al., 2010). 
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Characterization of LOX 
The mature LOX enzyme is synthesized via proteolytic cleavage of 50 kDa, N-glycosylated 
proenzyme (pro-LOX), into a 32 kDa, catalytically active, LOX, and a 18 kDa LOX-
propeptide (LOX-PP) (Sethi, Wordinger, & Clark, 2012; Smith-Mungo & Kagan, 1998). 
LOX activity has been shown to be critical in maintaining the stability and ultrastructural 
integrity of the basement membrane since LOX-mediated collagen IV and elastin 
crosslinks promote a functional assembly of the basement membrane (Gelse, Poschl, & 
Aigner, 2003; Poschl et al., 2004). The oxidative deamination of lysyl residues of collagen 
IV and elastin to allysine mediated by LOX is critical in achieving this process (Siegel, 
Pinnell, & Martin, 1970). The aldehyde products subsequently go through spontaneous 
condensation reactions to create covalent cross-links in extracellular matrices (ECM) 
(Rucker et al., 1998). In addition, proper LOX activity is needed to form a functional 
extracellular matrix by post-translationally modifying collagen fibrils to produce covalent 
cross-links that stabilize insoluble collagen. However, abnormally increased LOX-
mediated cross-linking may result in highly compacted collagen fibrils, leading to 
increased interfibrillar space and contributing to excess permeability (Grant et al., 1997; 
Ortolan et al., 2008). Excess synthesis of the ECM and subsequent stiffening of basement 
membrane could also contribute to compromised ultrastructure and functionality of the 
basement membrane (Chronopoulos et al., 2011; Yang et al., 2016). These suggest that the 
structural integrity of the basement membrane largely depends on LOX-mediated 
crosslinking, which needs to be carefully maintained and regulated. 
 
 7 
 
Figure 4. Structure of LOX and its mechanism of action. (A) Structure of the carbonyl 
cofactor of LOX, lysyl tyrosine quinone. (B) Mechanism of action of LOX. Figure taken 
from (Smith-Mungo & Kagan, 1998). 
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Figure 5. Graphical representation of collagen IV crosslinking. (A) Illustration of 
hydroxylysine aldehyde interactions between adjacent hydroxylysine residues of four 
collagen monomers (1-4), each containing conserved Hyl-Gly-His-Arg sequence, to form 
cross-links resulting in a mature collagen IV molecule. (B) Schematic representation of 
collagen crosslinking in which four collagen fibrils are in close juxtaposition and 
compacted, allowing maximum cross-linking. Blue colored area represents the 
interfibrillar space. Amended from (Bailey, Sims, & Light, 1984). 
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Figure 6. Synthesis of active LOX. Schematic representation shows the inactive 50 kDa 
pre-pro-LOX being processed through steps of glycosylation, incorporation of copper ion, 
translocation to the extracellular space, and proteolytic cleavage by procollagen C-
proteinase, producing the active 32 kDa LOX molecule and the 18 kDa LOX-PP molecule. 
Amended from (Smith et al., 2016). 
 
Role of LOX in diabetic retinopathy 
Previous studies from Dr. Sayon Roy’s lab have shown that HG condition promotes LOX 
overexpression in rat retinal endothelial cells (RRECs) and in retinas of diabetic rodents 
(Chronopoulos et al., 2010). Additionally, LOX activity has been shown to be upregulated 
in RRECs grown in HG condition (Chronopoulos et al., 2010). HG is also known to 
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compromise the activity of AKT, a pro-survival gene, in RRECs and thereby trigger 
apoptosis in these cells (Kim, Mecham, Trackman, & Roy, 2017). A recent study 
demonstrated that in diabetic mice, high levels of LOX were associated with lower AKT 
activity concomitant with increased activation of pro-apoptotic Bax and cleaved caspase-3 
genes (Kim et al., 2017). Therefore, in this thesis project, we aimed to investigate (1) 
whether reduced LOX level, using a LOX +/- animal model, confers protection against 
diabetes-induced retinal vascular lesions, and (2) whether targeting diabetes-induced LOX 
overexpression via intravitreal injections of LOX siRNA could hinder the development of 
retinal vascular cell loss and vascular leakage characteristic of diabetic retinopathy.  
 
 
 
Figure 7. LOX expression is upregulated in (A) RRECs grown in HG and (B) in 
retinas of diabetic rats. Amended from (Chronopoulos et al., 2010). 
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Figure 8. LOX siRNA effectively downregulates LOX expression. Western blot image 
shows LOX expression is significantly upregulated in cells grown in HG condition and is 
reduced when transfected with LOX siRNA. Amended from (Kim et al., 2017). 
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SPECIFIC AIMS 
 
The pathogenesis of diabetic retinopathy is characterized by microvascular lesions, such as 
accelerated endothelial cell death and vascular leakage in the diabetic retina. Studies have 
shown that abnormal thickening of retinal vascular basement membrane contributes to 
apoptosis and ultimately cell loss. A previous study from Dr. Sayon Roy’s lab has shown 
that HG condition promotes LOX overexpression in RRECs and in retinas of diabetic rats 
(Chronopoulos et al., 2010). Additionally, LOX activity is upregulated in RRECs grown 
in HG condition (Chronopoulos et al., 2010). A recent study found that HG-induced LOX 
overexpression promotes apoptosis in RRECs in vitro, and that LOX upregulation by 
diabetes was associated with compromised AKT activation and elevated Bax and caspase-
3 activity in vivo (Kim et al., 2017). These findings suggest that diabetes-induced abnormal 
LOX overexpression can promote apoptosis, which could lead to retinal vascular cell loss 
associated with diabetic retinopathy. Furthermore, HG-induced LOX overexpression was 
shown to promote increased cell monolayer permeability (Chronopoulos et al., 2010), 
suggesting that LOX overexpression may contribute to vascular leakage seen in diabetic 
retinopathy. However, whether reducing LOX overexpression shows protective effects 
against retinal vascular lesions associated with diabetic retinopathy was not well 
understood.  
 
As we are developing potential strategies to reduce diabetes-induced LOX overexpression, 
it is important to determine the effects of reduced LOX levels on a long-term basis. In 
particular, it remains unclear whether decreasing LOX upregulation on a long-term basis 
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can be sustained, and whether such beneficial effects in preventing apoptosis can reduce 
functional abnormalities, such as vascular permeability. Therefore, in Experiment 1, using 
the LOX +/- animal model, we examined whether reduced LOX expression confers 
protection against diabetes-induced retinal vascular cell loss and excess vascular 
permeability. 
 
Furthermore, a follow-up study (Experiment 2) was conducted to investigate whether 
lowering diabetes-induced LOX overexpression in rats via intravitreal injections of LOX 
siRNA show beneficial effects and assessed whether this approach halts the development 
of retinal vascular cell death and leakage in the retinal vasculature associated with diabetic 
retinopathy.  
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MATERIALS AND METHODS 
 
Animals  
Animal studies were conducted in adherence with the Association for Research in Vision 
and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision 
Research. For Experiment 1, twelve WT C57/BL6 albino male mice (Harlan Lab, Inc, 
Indianapolis, IN) and twelve LOX +/- mice bred into the C57/BL6 albino strain 
background kindly provided by Dr. Robert Mecham (Hornstra et al., 2003) were utilized 
for this study. The targeting construct deleted the ATG initiation codon of the LOX gene 
and replaced it with the PGK-Neo cassette in the opposite transcriptional orientation.  A 
detailed description on how the LOX allele was targeted is available in a study by (Hornstra 
et al., 2003). The animals’ genotypes were established by performing polymerase chain 
reaction (PCR) at the time of weaning and again at time of sacrifice using the animals’ tail 
tip DNA. PCR reactions were conducted using an enzyme blend solution (PCR Master 
Mix; Promega, Madison, WI) and contained the following primer sequences: Primer 1, 5’-
ACGGCTTGTGTAACTGCAAA–3’; Primer 2, 5’- TGAATGAACTGCAGGACGAG–
3’; Primer 3, 5’-ATCTGAGTCCCGGTCTTCCT-3’; Primer 4, 5’-
AGGTCCGGGAGACCTAAAGA-3’. Primers 1 and 2 amplify a ~1400-bp fragment 
representing the LOX +/- allele. Primers 3 and 4 amplify a ~1000-bp fragment representing 
the LOX +/+ allele. The LOX -/- genotype was not included in the study because it is 
perinatally lethal (Hornstra et al., 2003; Maki et al., 2002).  
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Six WT mice and six LOX +/- mice were intraperitoneally injected with STZ to induce 
diabetes at a concentration of 55 mg/kg body weight. In parallel, the remaining six WT 
mice and six LOX +/- mice were intraperitoneally injected with citrate buffer as vehicle 
and served as non-diabetic controls. Blood and urine glucose levels were monitored 2 or 3 
days post-STZ injection to verify the animals’ diabetes status. All animals were subjected 
to routine blood glucose measurement 2-3 times per week and at the time of sacrifice. 
Animals with blood glucose measurements of ~250 mg/dl represented the diabetic cohort. 
In addition, NPH insulin injections were administered in diabetic animals as needed to 
maintain blood glucose measurement of ~250 mg/dl. 16 weeks after the onset of diabetes, 
animals from all cohorts were sacrificed and retinas were isolated, and total protein was 
extracted from all samples. Experiments using animal samples were performed 
independently six times. 
 
For Experiment 2, in each of the three time points tested, 24 Sprague-Dawley rats were 
placed in 4 cohorts with 6 rats per group: non-diabetic (WT), diabetic (DM), diabetic 
intravitreally injected with LOX siRNA (DM+LOX siRNA), and diabetic intravitreally 
injected with scrambled siRNA (DM+Scram siRNA). Diabetes was induced and blood 
glucose levels were checked 2-3 days post injection to confirm diabetic status of the rats 
as described previously. At 1 month post-diabetes onset, 2 groups of rats, DM+LOX 
siRNA and DM+Scram siRNA, received monthly intravitreal injections of 3µM LOX 
siRNA, or scram siRNA, respectively, for one, two, or three intravitreal injections. Animals 
that received intravitreal injections and sacrificed after one month represent time point 1. 
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Second intravitreal injections were administered to the rest of the animals, and those 
sacrificed after one month represent time point 2. The remaining animals received a third 
intravitreal injection and sacrificed after one month, and they represent time point 3. 
Intravitreal injections were performed in the pars plana region with a syringe attached to a 
30-gauge needle; and the volume of freshly prepared siRNA was ~10 µL. The LOX siRNA 
used for this study specifically targeted two sequences of the mature rat LOX gene (5’-
CUGAAUCAGACUACAGUA-3’ and 5’-ACAAGTACTCCGACGACAA-3’) that do not 
share homology with each other. 
 
Western Blot  
To assess the expression of LOX, AKT, and AKT phosphorylation, total protein was 
isolated from diabetic or non-diabetic mouse and rat retinas, and subsequently used for WB 
analysis. Retinal tissues of diabetic or non-diabetic mice or rats were subjected to PBS 
washes and lysed in a solution composed of 10 mmol/l Tris, pH 7.5 (Sigma), 1 mmol/l 
EDTA, and 0.1% Triton X-100 (Sigma) to obtain total protein. Lysates from cells or retinal 
tissues were centrifuged at 13,000 g for 20 min at 4°C. Protein concentration from cell 
lysates and retinal tissues were determined by bicinchoninic acid protein assay (Pierce 
Chemical, Rockford, IL). Each lane was loaded with an equal amount of protein (20 μg) 
and electrophoresed together with a molecular weight marker (Bio-Rad, Hercules, CA) in 
a separate lane on a 10% SDS-polyacrylamide gel. After completion of the electrophoresis 
step, the protein samples loaded in the gel were transferred onto a PVDF membrane 
(Millipore, Billerica, MA) through a semi-dry apparatus following the Towbin’s procedure 
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(Towbin, Staehelin, & Gordon, 1979). The PVDF membrane was subjected to blocking 
using a 5% non-fat dry milk for 1.5 hours, followed by incubation overnight at 4°C with 
rabbit polyclonal LOX antibody (1:2000, Catalog #NB110-59729, Novus, Littleton, CO), 
rabbit polyclonal Ser473 phosphorylated AKT (p-AKT) antibody (1:1000, Catalog #9271, 
Cell Signaling), or total AKT antibody (1:1000, Catalog #9272, Cell Signaling) made in a 
Tris-buffered saline solution containing 0.1% Tween-20 (TTBS) and 5% bovine serum 
albumin. The membrane was subjected to TTBS washes the next day and exposed to a 
secondary antibody solution containing anti-rabbit IgG, AP-conjugated antibody (1:3000, 
Catalog #7054, Cell Signaling) in room temperature for 1 hour. The membrane was then 
washed with TTBS, subjected to Immun-Star chemiluminescent substrate (Bio-Rad), and 
exposed for development on X-ray film (Fujifilm, Tokyo, Japan). Equal loading of protein 
was verified through Ponceau-S staining after transfer, and by total AKT antibody (Cell 
Signaling). To quantify the LOX, p-AKT, and total AKT protein expression of tissue 
samples, densitometric analysis of the chemiluminescent signal was conducted at non-
saturating exposures and assessed using the Image J software (developed by Wayne 
Rasband, National Institutes of Health, Bethesda, MD; Version 1.52h).  
 
Isolation of Retinal Capillary Network 
The enucleated eyes were placed in 10% formalin for at least 24 hrs. The eyes were then 
cut in half with a razor blade, and the retinas were isolated and placed into 0.5M glycine 
for 24-48 hrs. Retinal trypsin digest (RTD) was performed as described (Kuwabara & 
Cogan, 1960). Each retina went through a series of washes with 3% trypsin, and the non-
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vascular mass of the retina was removed. The retinal capillary network was then isolated 
and mounted onto a silane-coated slide. 
 
Assessment of AC & PL 
RTDs were subjected to periodic acid-Schiff and hematoxylin staining as described (Tien, 
Muto, Barrette, Challyandra, & Roy, 2014). Ten representative fields were imaged using a 
digital camera attached to a microscope and the images were assessed for counts of AC 
and PL. Pericytes that were lost due to apoptosis were categorized as PL based on tell-tale 
histological alterations that can be identified as an empty shell in the capillary networks. 
When both vascular cell types, endothelial cells and pericytes, were absent, those vessels 
were considered AC. 
 
Terminal dUTP nick-end labeling Assay  
Terminal deoxynucleotidyl transferase-mediated uridine 5′-triphosphate-biotin nick end 
labeling (TUNEL) assay was carried out to examine the number of cells undergoing 
apoptosis in capillary networks of RTDs  using a commercially available kit (ApopTag In 
Situ Apoptosis Detection; Chemicon, Temecula, CA) as described previously (Tien et al., 
2014). Cells undergoing apoptosis can be analyzed in situ by nick-end labeling of DNA in 
single stranded genomic DNA fragments representative of apoptosis. RTD preparations 
were fixed in paraformaldehyde briefly, washed with 1x PBS, and permeated with a pre-
cooled mixture of a 2:1 ratio of ethanol/acetic acid. After additional PBS washes, RTD 
slides were exposed to equilibration buffer and were incubated for 1 hour with 
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deoxyribonucleotidyl transferase (TdT) enzyme in a moist chamber at 37°C. Following 
incubation, the slides were washed with 1× PBS and exposed to anti-digoxigenin 
peroxidase. Subsequently, the slides were washed in 1x PBS and mounted using anti-fade 
reagent (SlowFade Diamond Antifade, Cat#S36963; Invitrogen). At least five images 
representing random fields of the RTD slide were captured using a digital microscope (DS-
Fi1; Nikon) and assessed for TUNEL-positive cells. 
 
In Vivo Permeability Assay   
Retinal whole mounts were prepared for analysis of retinal vascular permeability as 
described with minor modifications (Oshitari et al., 2006). Briefly, tail vein injections of 
FITC-Dextran (FITC-Dex; 40 kDa) at 50 mg/kg body weight were carried out in mice from 
all groups. Following the tail vein injection, blood was collected and plasma assayed for 
fluorescence. Whole mount from one retina from each animal was prepared and the areas 
of extravasation representing focal leakages were assessed under fluorescence microscope. 
As such, fluorescence within vessels was not included in the assessment. Using the NIH 
ImageJ software (Version 1.52h), vascular leakage was quantified as mean fluorescence 
intensity of extravasated FITC-Dex times area of leakages divided by plasma fluorescence 
intensity Plasma fluorescence intensity was used to normalize the average retinal 
fluorescence intensity of each animal. This allows correction for variability in FITC-Dex 
tail vein injections between animals. At least five fields from the mid-retinal areas were 
analyzed for vascular leakage in a masked fashion. 
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Statistical Analysis 
Data are represented as mean  standard deviation. Values from the control group were 
normalized to 100% while values from other experimental groups were represented as 
percentages of the control. Normalized values were used for statistical analysis. A one-way 
ANOVA followed by Bonferroni’s post-hoc test was performed for comparisons between 
groups. P < 0.05 was noted as statistically significant.  
  
  
 21 
RESULTS 
 
Experiment 1: Effect of reduced LOX levels on retinal vascular cell loss and vascular 
leakage using the LOX +/- animal model. 
 
Genotyping of Control and Experimental Animals 
Genotypes of all mice used in the study were determined by PCR at weaning using tail tip 
DNA and then again at time of sacrifice. PCR-amplified fragments representing wild-type 
(LOX +/+) control mice showed a band near 1 kb while those of LOX +/- mice showed a 
band near 1.4 kb, confirming the heterozygous knockout genotype (Fig. 9A). 
 
Reduced LOX expression restores AKT activity in diabetic LOX +/- mouse retinas 
To assess whether diabetes affects LOX expression and AKT activity in diabetic mouse 
retinas, and whether reduced LOX levels modulates AKT activity in diabetic LOX +/- 
mouse retinas, Western Blot was performed. As expected, Western blot analysis showed 
that the diabetic mouse retinas exhibited a 40% increase in LOX expression compared to 
that of WT mouse retinas (140 ± 34% of WT vs 100 ± 29% of WT, P<0.05; n=6; Fig. 9B). 
In addition, the LOX +/- mice showed a 37% decrease in retinal LOX expression compared 
to that of WT mice (63 ± 14% of WT vs 100 ± 29% of WT, P<0.01; n=6; Fig. 9B). Retinal 
LOX expression level of diabetic LOX +/- mice was 38% lower compared to that of 
diabetic mice (102 ± 18% of WT vs 140 ± 34% of WT, P<0.05; n=6; Fig. 9B). Diabetic 
mouse retinas showed more than a two-fold decrease in the ratio of p-AKT to total AKT 
(44.2 ± 23% of WT vs 100 ± 33% of WT, P<0.05; n=6; Fig. 9C) compared to that of WT 
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mouse retinas. Reduced LOX levels of diabetic LOX +/- mouse retinas conferred a 35% 
increase in the ratio of p-AKT to AKT, indicating that AKT activity was restored (79.6 ± 
9% of WT vs 44.2 ± 23% of WT, P<0.05; n=6; Fig. 9C) compared to that of diabetic mouse 
retinas. Retinas of LOX +/- mice did not show a significant difference in the ratio of p-
AKT to AKT (90.8 ± 21% of WT vs 100 ± 33% of WT; P>0.05; n=6; Fig. 9C) compared 
to that of WT mouse retinas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Effect of reduced LOX expression on AKT activity in diabetic LOX +/- 
mouse retinas. (A) PCR analysis with mice tail tip DNA showing genotypes of LOX 
heterozygous knockout (+/-) and wild-type (WT) mice. The wild-type LOX allele (LOX 
+/+) is represented by a band at 1 kb, whereas the disrupted allele (LOX +/-) shows a band 
at 1.4 kb. (B) Graphical illustration of cumulative data shows LOX expression is 
normalized in the diabetic LOX +/- (DLOX +/-) mice, and that diabetes (DM) significantly 
upregulates LOX expression. (C) Graphical illustration of cumulative data shows AKT 
activity is significantly decreased in diabetic mouse retinas. Interestingly, AKT activity is 
increased in DLOX +/- mouse retinas compared to that of diabetic mouse retinas. Data are 
expressed as mean ± SD. * = P<0.01; ** = P<0.05.  
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Reduced LOX expression protects against the development of AC and PL in diabetic 
LOX +/- mouse retinas 
To determine the effect of diabetes and reduced LOX levels in the development of AC and 
PL, retinal trypsin digestion was performed. As expected, RTD data showed that the 
diabetic mouse retinas exhibited a 125% increase in the number of AC (225 ± 8% of WT 
vs 100 ± 23% of WT, P<0.01; n=6; Fig. 10A) and 390% increase in the number of PL (490 
± 60% of WT vs 100 ± 56% of WT, P<0.01; n=6; Fig. 10B) compared to that of WT mouse 
retinas. Reduced LOX levels of diabetic LOX +/- mouse retinas played a protective role 
by reducing the development of AC by 88% (137 ± 15% of WT vs 225 ± 8% of WT, 
P<0.05; n=6; Fig. 10A) and PL by 313% (177 ± 81% of WT vs 490 ± 60% of WT, P<0.05; 
n=6; Fig. 10B) compared to those of diabetic mouse retinas. There was no significant 
difference in the numbers of AC (82 ± 30% of WT vs 100 ± 23% of WT; P>0.05; n=6; Fig. 
10A) and PL (100 ± 83% of WT vs 100 ± 56% of WT; P>0.05; n=6; Fig. 10B) in the LOX 
+/- mouse retinas compared to those of WT mouse retinas.  
 
 
 
 
 
 
 
 
Figure 10. Reduced LOX level prevents the development of AC and PL in diabetic 
LOX +/- mouse retinas. Graphical illustrations of cumulative data show that reduced LOX 
levels in the DLOX +/- mouse retina exhibited a protective effect against the development 
of (A) AC and (B) PL. Data are expressed as mean ± SD. * = P<0.01; ** = P<0.05. 
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Reduced LOX expression protects against diabetes-induced apoptosis of retinal vascular 
cells 
To determine the effect of diabetes and reduced LOX levels on retinal vascular cell 
apoptosis, TUNEL assay was carried out on retinal capillary networks of RTDs in all 
groups. Diabetic mouse retinas exhibited a 281% increase in the number of TUNEL-
positive cells (381 ± 37% of WT vs 100 ± 61% of WT; P<0.01; n=6; Fig. 11A). 
Interestingly, reduced LOX levels in diabetic LOX +/- mouse retinas led to a decrease in 
the number of TUNEL-positive cells (191 ± 97% of WT vs 381 ± 37% of WT; P<0.05; 
n=6; Fig. 11A) compared to that of diabetic mouse retinas. No significant difference was 
observed in the number of TUNEL-positive cells between LOX +/- mouse retinas and WT 
mouse retinas (157 ± 90% of WT vs 100 ± 61% of WT; P>0.05; n=6; Fig. 11A). 
 
 
 
 
 
 
 
 
 
 
Figure 11. Reduced LOX level protects against diabetes-induced apoptosis of vascular 
cells and prevents vascular leakage in retinal capillary networks of diabetic LOX +/- 
mice. (A) Graph of cumulative data showing that retinal capillary networks of diabetic 
mice exhibited an increase in number of TUNEL-positive cells compared to that of WT 
mice, while retinal capillary networks of DLOX +/- mice showed reduced number of 
TUNEL-positive cells compared to that of diabetic mice. (B) Graphical illustration of 
cumulative data shows reduced LOX levels in the DLOX +/- mouse retina exhibit reduced 
vascular permeability compared to that of diabetic mouse retina. Data are presented as 
mean ± SD. * = P<0.01; ** = P<0.05. 
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Reduced LOX expression protects against diabetes-induced vascular leakage 
To determine the effect of diabetes and reduced LOX levels on retinal vascular 
permeability, retinal vascular leakage was assessed following tail vein injection of FITC-
Dex. As expected, retinal capillary networks of diabetic mice showed a significant increase 
in FITC-Dex extravasation (243 ± 7% of WT vs 100 ± 30% of WT; P<0.01; n=6; Fig. 11B) 
compared to that of retinal capillary networks of WT mice. Interestingly, reduced LOX 
levels in diabetic LOX +/- mice protected against diabetes-induced retinal vascular leakage 
as shown by reduced FITC-Dex extravasation (164 ± 12% of WT vs 243 ± 7% of 
WT; P<0.01; n=6; Fig. 11B). The retinal capillary networks of LOX +/- mice did not 
exhibit a significant difference in FITC-Dex extravasation (129 ± 15% of WT vs 100 ± 
30% of WT; P>0.05; n=6; Fig. 11B) compared to that of retinal capillary networks of WT 
mice.  
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Experiment 2: Therapeutic potential of LOX siRNA against retinal vascular lesions 
in diabetic retinopathy 
 
Effects of LOX siRNA on Diabetes-induced LOX Protein Overexpression in Rat Retinas 
At 2, 3, and 4 months after the onset of diabetes, retinal LOX protein expression levels 
were significantly increased (151 ± 31% of WT, 159 ± 23% of WT, and 163 ± 18% of WT, 
respectively, P < 0.05; n=6; Fig 12A, 12B, 12C) compared to those of non-diabetic rats. 
Importantly, LOX protein levels were significantly decreased in diabetic rat retinas that 
received LOX siRNA compared to those of diabetic rats across all three time points (94 ± 
42% versus of WT, 124 ± 15% versus  of WT, and 120 ± 27% of WT, respectively, P < 
0.05; n=6; Figs 12A, 12B, 12C). As expected, diabetic rat retinas that received scrambled 
siRNA did not demonstrate a significant change in LOX protein expression compared to 
those of untreated diabetic rats. 
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Figure 12. Effects of diabetes and LOX siRNA on LOX expression in rat retinas after 
1, 2, or 3 intravitreal injections. Representative Western blot images show (A) 2, (B)  3, 
and (C) 4 months after the onset of diabetes significantly upregulates LOX expression. 
Graphical illustration of cumulative data shows that administration of LOX siRNA 
normalizes LOX expression in diabetic rat retinas. All data have been normalized using β-
actin correction. Data are expressed as mean ± SD. * = WT vs DM; DM vs DM+LOX 
siRNA; DM+LOX siRNA vs DM+Scram siRNA; P<0.05; n=6. Amended from (Song, 
Kim, Nguyen, & Roy, 2018). 
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Effects of LOX siRNA on AC and PL in Diabetic Rats 
RTD analysis demonstrated a significant increase in the number of ACs (188 ± 20% of 
WT, 191 ± 12% of WT, and 272 ± 6% of WT respectively, P < 0.05; n=6; Fig. 13B) and 
PL (191 ± 12% of WT, 305 ± 12% of WT, and 314 ± 44% of WT, respectively, P < 0.05; 
n=6; Fig. 13C) in diabetic rat retinas compared to those of non-diabetic rats across all three 
time points. Interestingly, retinas of diabetic rats that received LOX siRNA exhibited 
reduced number of ACs (118 ± 4% of WT, 136 ± 9% of WT, and 140 ± 17% of WT, 
respectively, P < 0.05; n=6; Fig. 13B) and PL (187 ± 25% of WT, 185 ± 20% of WT, and 
143 ± 36% of WT respectively, P < 0.05; n=6; Fig. 13C) compared to those of untreated 
diabetic rats across all three time points. Rats intravitreally injected with scrambled siRNA 
did not exhibit a significant difference in the number of AC and PL compared to those of 
untreated diabetic rats.  
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Figure 13. Effects of diabetes and LOX siRNA on AC and PL development after 1, 2, 
or 3 intravitreal injections. (A) Representative RTD images show the number of AC 
(long arrows) and PL (arrowheads) is increased in the retinas of diabetic rats compared to 
those of wild-type rat.  Scale bar = 20 μm. Graphical illustration of cumulative data shows 
1, 2, or 3 intravitreal injections of LOX siRNA significantly reduced the number of (B) AC 
and (C) PL. Data are expressed as mean ± SD. * = P<0.05; n=6. ** = P<0.01; n=6. TP1 = 
timepoint 1; TP2 = timepoint 2; TP3 = timepoint 3. Amended from (Song et al., 2018). 
 
 
Effects of LOX siRNA on Retinal Capillary Leakage in Diabetic Rats  
Retinal capillary networks of diabetic rats exhibited significantly increased vascular 
leakage compared to those of non-diabetic rats across all three time points (200 ± 44% of 
WT, 314 ± 89% of WT, and 383 ± 75% of WT, respectively, P < 0.01; n=6; Figs 14B, 14D, 
14F). Importantly, vascular permeability was significantly reduced in rats intravitreally 
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injected with LOX siRNA (128 ± 47% of WT, 200 ± 70% of WT, 166 ± 52% of WT, 
respectively, P < 0.05; n=6, Figs 14B, 14D, 14F), while scrambled siRNA injection yielded 
no significant effect. 
 
 
Figure 14. Effects of diabetes and LOX siRNA on vascular permeability after 1, 2, or 
3 intravitreal injections. (A) Representative IVP image shows vascular permeability 
significantly increases 2 months after the onset of diabetes. (B) Graphical illustration of 
cumulative data shows LOX siRNA significantly reduced vascular leakage after 1 
intravitreal injection. Data are expressed as mean ± SD. ** = WT vs DM; P<0.01; n=6. * 
= DM vs DM+LOX siRNA; DM+LOX siRNA vs DM+Scram; P<0.05; n=6. (C) 
Representative IVP image shows vascular permeability significantly increases 3 months 
after the onset of diabetes. (D) Graphical illustration of cumulative data shows LOX siRNA 
significantly reduced vascular leakage after 2 intravitreal injections. Data are expressed as 
mean ± SD. ** = WT vs DM; P<0.01; n=6. * = DM vs DM+LOX siRNA; DM+LOX 
siRNA vs DM+Scram; P<0.05; n=6. (E) Representative IVP image shows vascular 
permeability significantly increases 4 months after the onset of diabetes. (F) Graphical 
illustration of cumulative data shows LOX siRNA significantly reduced vascular leakage 
after 3 intravitreal injections. Data are expressed as mean ± SD. *** = WT vs DM; DM vs 
DM+LOX siRNA; DM+LOX siRNA vs DM+Scram; P<0.001; n=6. Figure taken from 
(Song et al., 2018). 
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DISCUSSION 
 
Findings from this thesis project provide novel evidence that reducing LOX overexpression 
in the diabetic milieu confers protection against diabetes-induced apoptosis of retinal 
vascular cells, development of AC and PL, and retinal vascular leakage. Data from 
Experiment 1 support findings from previous reports that normalizing LOX overexpression 
plays a protective role against cell loss, at least in part, by improving AKT activity (Kim 
et al., 2017). Interestingly, genetic reduction of 50% LOX expression showed no 
observable adverse effects in the retina or in other tissues. These results confirm that 
diabetes-induced LOX overexpression promotes retinal vascular lesions, and that LOX 
downregulation is safe and effective in preventing these lesions associated with diabetic 
retinopathy. 
 
The results from Experiment 2 indicate that diabetes-induced LOX overexpression can 
promote the development of retinal vascular cell apoptosis and increased vascular 
permeability. This study shows a novel finding that downregulation of LOX expression via 
intravitreal injections of LOX siRNA is sufficient to prevent vascular cell loss and capillary 
leakage in the diabetic retinas. In addition, the beneficial effect of siRNA treatment was 
seen not only on a short-term basis, but also with a regimen involving long-term treatment. 
Overall, use of intravitreal injections of LOX siRNA shows promise in modulating LOX 
gene overexpression and protecting against vascular lesions in diabetic retinas.  
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Although the exact mechanism underlying LOX overexpression-mediated vascular cell 
loss is not well known, our recent study suggests that LOX overexpression compromises 
AKT phosphorylation, which can promote apoptosis (Kim et al., 2017). In accordance with 
our finding that HG promotes LOX overexpression and inhibits cell proliferation 
(Chronopoulos et al., 2010; Kim et al., 2017), studies from other groups have also 
confirmed that LOX overexpression lowers cell proliferation, induces apoptosis (Xu, 
Wang, & Xu, 2013), and inhibits cell growth (Sung et al., 2014). Overall, these findings 
offer valuable insights into the role of abnormal LOX overexpression in promoting 
vascular cell death in the diabetic retina. 
 
A multifaceted mechanism may underlie increased LOX-mediated pro-apoptotic effects. 
A study suggests that the enzymatic activity of intracellular LOX can directly limit the 
growth of the nucleus and subsequently prevent cell proliferation (Saad, Torres, Wang, & 
Graham, 2010). In parallel, a study demonstrated that lentiviral-mediated LOX 
overexpression and resultant increase in the secretion of mature LOX enzyme exert pro-
apoptotic effects on human vascular smooth muscle cells, providing evidence that 
extracellular LOX enzymatic activity also contributes to apoptosis (Varona et al., 2018). 
Other studies report that the pro-peptide region of LOX may also be involved in inducing 
apoptosis. (Nareshkumar, Sulochana, & Coral, 2018). Interestingly, pro-LOX, the 
precursor to LOX and LOX-PP, has been shown to possess the ability to promote apoptosis 
(Contente, Yeh, & Friedman, 2009). At this time, the distinction between LOX and LOX-
PP in inducing apoptosis is under intensive study. While it is possible that modulation of 
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LOX-PP or pro-LOX may contribute to cell death, our current findings provide evidence 
that LOX is pro-apoptotic. Overall, these studies suggest that diabetes-mediated LOX 
overexpression can contribute to cell loss, at least in part, by increased activity of pro-LOX, 
LOX-PP, and/or LOX.  
 
While acute downregulation of LOX overexpression using LOX siRNA or BAPN protects 
against HG-induced apoptosis and excess cell monolayer permeability in vitro, it is 
currently unknown how long-term downregulation of LOX affects cell viability in the 
diabetic milieu. Previous studies using the LOX heterozygous knockout mice showed no 
adverse effects in cross-linking activity and collagen content in the aorta and lung tissues 
between the LOX +/- mice and control mice (Hornstra et al., 2003; Maki et al., 2002). 
Similarly, in studies related to Experiment 1, no adverse effects due to reduced LOX level 
were observed; specifically, there was no observable difference in retinal vascular cell loss 
and breakdown of BRB in the retinal vasculature of LOX +/- animals. In conclusion, 
findings from the Experiment 1 indicate that decreasing diabetes-induced LOX 
overexpression to normal levels can confer protection against retinal vascular cell loss and 
vascular leakage. These findings suggest that targeting LOX upregulation may be 
beneficial against the development of retinal vascular lesions seen in diabetic retinopathy. 
 
In the context of human subjects with diabetes, only limited information is available 
regarding LOX expression in the retina. A recent study from Dr. Sayon Roy’s lab found 
that in vitreous samples from diabetic patients with advanced diabetic retinopathy, there 
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was a significant elevation in LOX levels compared to those of non-diabetic subjects 
(Subramanian, Stein, Ness, Siegel, & Roy, 2018; 268/69). While it is currently unknown 
whether LOX expression is altered in diabetic conditions in retinal cell types besides 
vascular cells, LOX was found to be abundantly expressed in the inner surface of the 
pigmented epithelia in the photoreceptor layer (Hayashi et al., 2004). Interestingly, LOX 
expression was found to be increased at the mRNA level in retinal pigmented epithelial 
cells grown under HG condition (Coral, Madhavan, Pukhraj, & Angayarkanni, 2013). 
Further studies are needed to shed light into the effects of HG- or diabetes-induced LOX 
changes in other retinal cell types. 
 
Previously, a study from Dr. Sayon Roy’s lab has demonstrated that retinal endothelial 
cells grown in HG condition exhibit LOX overexpression and increased LOX activity, 
which can lead to increased cell monolayer permeability (Chronopoulos et al., 2010). In 
both Experiment 1 and Experiment 2, we demonstrate that by reducing diabetes-induced 
retinal LOX overexpression, vascular leakage can be ameliorated in the retinas of diabetic 
rats. When retinal vascular basement membrane structure is compromised, it is known to 
contribute to vascular leakage in diabetic retinopathy (Chronopoulos et al., 2010; 
Chronopoulos et al., 2011; Roy, Kim, Hernandez, Simo, & Roy, 2015; Trudeau et al., 
2011). We hypothesize that by lowering LOX overexpression, the integrity and assembly 
of the basement membrane ultrastructure could be improved and thereby protect against 
vascular leakage. Similar to our findings, advanced glycation end products, which are 
prominent inducers of diabetic retinopathy pathogenesis (Hammes et al., 1999; Katagiri et 
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al., 2018; Stitt, 2003), have been shown to increase LOX expression (Adamopoulos et al., 
2016), lead to excess crosslinking of collagen, compromise the architecture of the basement 
membrane (Defronzo, 1997), and contribute to vascular leakage (Boyd-White & Williams, 
1996).  
 
In addition to promoting vascular cell loss and vascular leakage, LOX overexpression has 
associated with excess the synthesis of LOX-PP, which subsequently influences the FAK 
activity (Nareshkumar et al., 2018) and RAS-mediated signaling pathways (Sato et al., 
2013; Zhao et al., 2009), leading to NF-kB inactivation and ultimately result in apoptotic 
cell death (Jeay, Pianetti, Kagan, & Sonenshein, 2003; Li et al., 2010). Interestingly, a 
study found that LOX overexpression led to basement membrane stiffening, promoting 
endothelial cell activation and leukocyte accumulation in diabetic mouse retinas (Yang et 
al., 2016). Moreover, inhibiting LOX was shown to protect against macrophage infiltration 
in inflammatory-stage lung tissue to prevent further inflammation (Cheng et al., 2014).  
 
In Experiment 2, LOX siRNA was administered through the intravitreal injection approach 
as this is known to be the most efficient route in reaching the highest concentration and 
efficacy. Nonetheless, it is also known that siRNA delivered into the posterior chamber can 
deplete via diffusion through the BRB into the systemic circulation. While intravitreally 
injected LOX siRNA could ultimately localize into the systemic circulation, the amount 
would likely be quite small as only ~400 ng is being administered through intravitreal 
injection. Intravitreally injected siRNA also showed no signs of systemic toxicity or 
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inflammation in settings of clinical trials (Nguyen, Schachar, Nduaka, Sperling, Basile, 
Klamerus, Chi-Burris, Yan, Paggiarino, Rosenblatt, Aitchison, et al., 2012). Furthermore, 
a study has shown that intravitreal injection of VEGF-A siRNA successfully resulted in 
the siRNA localizing to the retina and distributing throughout the eye (Garba & Mousa, 
2010). Because all siRNAs are constituted of 21-23 nucleotides (Schroeder, Levins, Cortez, 
Langer, & Anderson, 2010), the distribution and localization of LOX siRNA in the eye is 
likely to be similar as siRNAs.  
 
The efficacy of siRNA as a treatment modality has been tested in clinical trials for ocular 
complications (Kaiser et al., 2010; Moreno-Montanes et al., 2014; Nguyen, Schachar, 
Nduaka, Sperling, Basile, Klamerus, Chi-Burris, Yan, Paggiarino, Rosenblatt, Aitchison, 
et al., 2012; Nguyen, Schachar, Nduaka, Sperling, Basile, Klamerus, Chi-Burris, Yan, 
Paggiarino, Rosenblatt, Khan, et al., 2012; Nguyen, Schachar, Nduaka, Sperling, 
Klamerus, et al., 2012) such as diabetic macular edema (Nguyen, Schachar, Nduaka, 
Sperling, Basile, Klamerus, Chi-Burris, Yan, Paggiarino, Rosenblatt, Aitchison, et al., 
2012) and age-related macular degeneration (Nguyen, Schachar, Nduaka, Sperling, 
Klamerus, et al., 2012). Findings from these clinical trials have shown positive indications 
that siRNA treatment may be useful. In particular, the combined approach using 
ranibizumab, an antibody against VEGF-A, and PF-655 siRNA, a synthetic siRNA 
inhibiting the expression of RTP801, a stress-inducible adaptor protein that inactivates the 
cell regulatory mammalian target of Rapamycin (mTOR) pathway, showed more efficacy 
in treating neovascular age-related macular degeneration compared to treatment with 
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ranibizumab alone (Nguyen, Schachar, Nduaka, Sperling, Klamerus, et al., 2012).  
Accordingly, the use of LOX siRNA in protecting against vascular lesions in the diabetic 
retina may show promise as a supplemental approach for treating diabetic retinopathy. 
While the effects of long-term siRNA use are not well known, in line with previous studies 
(Mao, Gorbatyuk, Rossmiller, Hauswirth, & Lewin, 2012; Roy, Nasser, Yee, Graves, & 
Roy, 2011) findings from Experiment 2 suggest that LOX siRNA intravitreal injection 
shows promise as a gene modulatory approach to treat vascular lesions in diabetic retinas. 
Taken together, the findings from this project suggest that abnormal LOX overexpression 
may be a potential therapeutic target to protect against retinal vascular lesions associated 
with diabetic retinopathy.  
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